Psyence Biomedical Ltd. PBM
Set alert
As of Nov 3, 12:00 PM ET
- YTD
- -88.90%
- 1 year
- -97.21%
- Open
- 3.18
- Prev close
- 3.18
- Mkt cap
- 12.45M
- Vol
- 116.09K
- Avg vol
- 79.10K
- EPS
- -12.56
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.16
- High
- 3.33
- Forward P/E
- 0.00
- Beta
- -0.42
- Short ratio
- 0.08
- Inst. own
- 37.09%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.68
- 200-d avg
- 36.44
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 26, 2024Split: 1 for 75
- May 5, 2025Split: 1 for 8
- Jan 20, 2026Split: 1 for 6
- Feb 2, 2026Split: 1 for 6.25
Signals (55)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 13, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| RSI: Overbought | Sep 23, 2026 | 1 month ago |
| RSI: Overbought | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| RSI: Overbought | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Jan 30, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
| RSI: Oversold | Dec 19, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
Newest 20 of 55.
Key statistics
- Market cap
- 2.01M
- Enterprise value
- 49.51M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -586.50
- Beta
- -0.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -1.71M
- Total cash
- 733.19K
- Total debt
- 7.66M
- Return on equity
- 0.00%
- Shares outstanding
- 845.06K
- Short % of float
- 1.34%
- 50-day average
- 4.68
- 200-day average
- 36.44
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- psyencebiomed.com
News
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Psyence Biomedical Completes Its Additional Investment In PsyLabs Of $2,599,896
- Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
- Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient
- Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
- Psyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S.
- Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
- Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs
- Psyence BioMed Announces Strategic Ibogaine Investment
- Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Your note
Sign in to keep a note on PBM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 5, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 0.03% | 16,431 | 39.10K | Sep 29, 2024 |
| Cantor Fitzgerald, L.P. | 0.01% | 4,493 | 10.69K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.00% | 2,257 | 5.37K | Sep 29, 2024 |
| Stonehage Fleming Financial Services Holdings Limited | 0.00% | 1,073 | 2.55K | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 645 | 1.53K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.00% | 613 | 1.46K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.04% | 25,272 | 60.15K | Oct 30, 2024 |